Superstring Capital Management LP I Mab Call Options Transaction History
Superstring Capital Management LP
- $102 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMAB
# of Institutions
52Shares Held
34.5MCall Options Held
25KPut Options Held
42.3K-
Janus Henderson Group PLC London, X07.99MShares$33.3 Million0.01% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$24.9 Million0.68% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$17.4 Million3.04% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.34MShares$13.9 Million0.02% of portfolio
-
Morgan Stanley New York, NY2.23MShares$9.31 Million0.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $347M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...